micro-community-banner
 
  • Saved

3w
BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares - PubMed

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41481736/

Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for...

Study demonstrates BCMA/CD19 CAR T cell therapy induces durable, drug-free remission in refractory myasthenia gravis, with B-cell reconstitution patterns, proteomic shifts, and FCRL5 identified as a potential relapse biomarker.

  • Saved

argenx

Sponsored

Discover My VYVGART® Path, a comprehensive patient support program

Get personalized support throughout your patient's treatment journey. Enroll your patients online or via fax and get them started with VYVGART Hytrulo or VYVGART.

Advertisement

argenx logo

For US audiences only.

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

© 2025 argenx US-VYV-25-00177 V1 11/2025. All Rights Reserved.

  • Saved

1mo
Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA - PubMed

Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41389129/

These results from US clinical practice suggest greater reductions in OCS and NSIST concomitant therapy for patients treated with ravulizumab or eculizumab compared with efgartigimod.

US claims analysis showed greater reductions in oral corticosteroid dose and nonsteroidal immunosuppressant use with C5 inhibitors than with FcRn antagonism among generalized myasthenia gravis patients.

  • Saved

1mo
Patient journey in generalized myasthenia gravis in the United States: Barriers to timely diagnosis and proposed solutions - PubMed

Patient journey in generalized myasthenia gravis in the United States: Barriers to timely diagnosis and proposed solutions - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41319378/

Patients with gMG experienced longer diagnostic journeys from seeking care to diagnosis than from symptom onset to seeking care, and faced barriers to diagnosis based on race, ethnicity, and gender....

Mixed-methods data from patients and clinicians show long diagnostic delays in gMG, with disparities by gender and race. Barriers include misattribution of symptoms and limited specialty access; solutions emphasize system-level improvements.

  • Saved

1mo
Myasthenia gravis in 2025: five new things and four hopes for the future - PubMed

Myasthenia gravis in 2025: five new things and four hopes for the future - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39987373/

The last 10 years has brought transformative developments in the effective treatment of myasthenia gravis (MG). Beginning with the randomized trial of thymectomy in myasthenia gravis that demonstrated efficacy of...

A contemporary review outlining major therapeutic advances in myasthenia gravis, evolving treatment algorithms, biomarker developments, and emerging challenges in older adults, while highlighting future priorities including rapid diagnostics, neuromuscular protection, and durable immune-targeted therapies.